Implementing a System-wide 340B Program



Similar documents
The PHS 340B Drug Pricing Program

The 340B Drug Pricing Program: The Basics

340B Drug Pricing Program January 15, 2015

The 340B Drug Pricing Program: The Basics INTEGRITY ACCESS VALUE 1

HRSA Pharmacy Services Support Center: The 340B Access Resource

340B Drug Pricing Program

Maximizing the 340B Drug Discount Program: A Webinar for Finance Executives in 340B Hospitals Webinar

The 340B Drug Pricing Program. Ariel Winter and Daniel Zabinski November 6, 2014

UPDATES ON 340B Where do we go from here?

Federal 340B Drug Pricing Program

340B Drug Discount Program Overview and Emerging Issues

340B Drug Pricing Program 340B Contract Pharmacy

The 340B Program: New Developments and New Opportunities for CAHs and Others. Todd Nova Hall Render

B & Prime Vendor Program Update

CPAs and ADVISORS. experience access // 340B QUALIFICATIONS, BENEFITS AND CURRENT FOCUS

PHARMACY CARE FQHCs AND 340B PROGRAM

10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR

The 340B Drug Pricing Program: The Basics

XXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management

340B Drug Discount Program Identifying risks and internal audit focus areas

340B Drug Discount Program Improving Compliance to Protect Savings and Be Audit Ready. Suzanne Herzog Founding Director Rx X Consulting

Finally... maybe? The Long Awaited 340B Mega Guidance. Georgia Healthcare Financial Management Association. October 2015

The 340B Drug Discount Program Overview, Compliance Issues and Interplay with Medicare and Medicaid

Overview of Drug Pricing for Public Programs

Alabama Department of Public Health Drug Purchasing Programs: 340B and MMCAP. Alabama Department of Public Health 8/20/2012

October 27, Attention: RIN 0906-AB08. RE: 340B Drug Pricing Program Omnibus Guidance. Dear Captain Pedley:

Keep Your Savings: 340B Audits and Ensuring Compliance

4/3/2015 WHAT IS 340B? DISCLOSURE. No conflicts of interest to disclose

The Pharmacy 340B Program- Compliance & Internal Audit Strategies. for Covered Entities. Matthew D. Vogelien Huron Healthcare

MEDICARE PART B DRUGS. Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals

340B Drug Pricing Program: Overview and Recent Developments

340B: ARE WE MONITORING COMPLIANCE EFFECTIVELY AND EFFICIENTLY

Hemophilia Treatment Center Manual for Participating in the Drug Pricing Program Established by Section 340B of the Public Health Service Act

GAO DRUG PRICING. Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement

340B DISCOUNT DRUG PROGRAM OVERVIEW

340B Drug Pricing Program: Recent Developments and Compliance Update

SUMMARY: The Health Resources and Services Administration (HRSA) administers section

(RIN) 0906-AB08; 340-B

Overview of the 340B Drug Pricing Program

C. Covered 340B drugs, as found in section 1927 (k)(2) of the Social Security Act, include the following outpatient drugs:

Eligibility of Rural Hospitals for the 340B Drug Discount Program

The 3 Keys to Success in Your 340B Program. Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company

340B Benefits Some, Not Others

The Federal 340B Drug Discount Program: A Primer

SECTION 12 - REIMBURSEMENT METHODOLOGY

Health IT Policy Committee Meeting. Data Update. March 10, 2015

OPA DATABASE GUIDE PUBLIC USERS - RECERTIFICATION FOR AUGUST 2013 VERSION 5.2.1

340B Policy Landscape

The Bridge to 340B Comprehensive Pharmacy Services Solutions in Underserved Populations

Ensuring Integrity in use of 340B pricing: Responsibility, Compliance, Accountability

340B University Page 1 340B Manager and Coordinator Job Description Template

Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements

The Medicaid EHR Incentive Program: Overview, Program Integrity & Compliance

340B UNIVERSITY Las Vegas Edition. May 31, 2014

Pharmaceutical Marketplace Dynamics Expenditures, Distribution, Coverage, Pricing


kaiser medicaid commission on and the uninsured May 2009 Community Care of North Carolina: Putting Health Reform Ideas into Practice in Medicaid

COST OF DISPENSING PRESCRIPTION DRUGS TO MEDICAID MEMBERS SURVEY

LEGISLATIVE AUDITOR VIRGINIA WEST. Department of Health and Human Resources. Full Performance Evaluation PERFORMANCE EVALUATION AND RESEARCH DIVISION

340B DRUG DISCOUNT PROGRAM OMNIBUS GUIDANCE. Presented by the American Bar Association Health Law Section and Center for Professional Development

When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC

Expanding 340B Participation: The Provider-Based Challenge

HB 686-FN-A - AS INTRODUCED. establishing a single payer health care system and making an appropriation therefor.

Challenges and Opportunities

CONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE

Medical Care Advisory Committee. Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission

Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. Quarter Ending September 2015

Printed copies are for reference only. Please refer to the electronic copy of this policy for the latest version.

GROWTH OF THE 340B PROGRAM: PAST TRENDS, FUTURE PROJECTIONS

Transcription:

Implementing a System-wide 340B Program An Overview Steve Pitzer System Executive, Supply Chain Management CHRISTUS Health Sam Colletti, RPh Director of Enterprise Accounts- CHRISTUS Health Broadlane

Objectives CHRISTUS Supply Chain Management Review of 340B Program CHRISTUS Implementation of a System-Wide 340B Program Indentifying appropriate Staff, Departments, resources Identify challenges and prohibitions to facilities Tracking results Update of Current Legislative Activity and Implications to Eligible Healthcare Facilities

CHRISTUS Health Supply Chain in Collaboration with Broadlane and Supplier Partnerships Steve Pitzer, System Director Supply Chain Management

CHRISTUS Health 1999 two historic Catholic charities formed CHRISTUS Health: Sisters of Charity Health Care System Incarnate Word Health System Mission: To extend the healing ministry of Jesus Christ Top 10 Catholic health system in U.S. 43 hospitals / 16 long-term acute care facilities across 8 states and Mexico Net patient revenues exceeding $2.6 billion Charity Care Community Benefit 2.8 million Assets totaling more than $4.3 billion Supplies, Purchased Services, and Energy $957million 4 Confidential Not For Distribution

Supply Chain Collaboration Quality & Safety Savings = Savings RASMUS Information Management variability = predictable outcomes Waste leads to risk MD s and stakeholders Listen and educate High value vs. Low impact Multi-disciplinary Educational Clinical & Non-Clinical Committees Pharmacy & Nursing Flexible Multi-disciplinary Physician preference items 5 Confidential Not For Distribution

CHRISTUS Health Committee collaboration 6 Confidential Not For Distribution

Inclusive approach has driven performance improvements Collaboration and input from key corporate stakeholders results in less variability through system standards, formulary development, and increased compliance 7 Confidential Not For Distribution

Supply Expense as a % of Total Operating Revenue Fiscal Year % of Total Operating Revenue 2002 17.06% 2003 17.86% 2004 18.67% 2005 17.99% 2006 17.33% 2007 17.88% 2008 17.28% 8 Confidential Not For Distribution

Adding to Community Benefit Managing Resources is a cornerstone of providing community benefit CHRISTUS examines every piece of the supply chain for opportunities Pharmacy Indigent drug recovery program from manufacturers 340B Program Community grants for local outreach programs 9 Confidential Not For Distribution

Implementing a System-wide 340B Program Sam Colletti, RPh Director of Enterprise Accounts- CHRISTUS Health Broadlane

340B Drug Pricing Program The initial barriers to hospital pharmacy Awareness Fear of Federal Audits and Regulation Program created in 1992 Provides discounts on outpatient drugs to various covered entities Manufacturers that participate in Medicaid must sign an agreement to participate in 340B Drug Pricing Program

340B Covered Entities HRSA Grantees CHC, HTC, RW CDC Grantees STD, TB Family Planning Clinics Urban 638 Tribal Programs Federally Qualified Health Center (FQHC) Look-A-likes Disproportionate Share Hospitals (DSH)

PPS Hospitals* with a Disproportionate Patient Percentage Ratio Greater than 27.32 and Core Based Statistical Areas (CBSAs), 2004 RURAL DSH HOSPITALS Alaska and Hawaii not to scale Metropolitan Status (# of Counties) Hospitals by Type of Control (# of Hospitals) Sources: US Census Bureau, 2003; CMS Provider Specific File, 2004; CMS OSCAR File, 2003. Produced By: North Carolina Rural Health Research and Policy Analysis Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill. Metropolitan (1090) Micropolitan (690) Neither (1361) For Profit (79) Government (175) Non-profit (193) *Note: Only hospitals outside of metropolitan counties are included. Hospitals are mapped to the ZIP code centroid. TOTAL - 447

Additional Eligibility Requirements In addition to meeting the 340B DSH Adjustment Percentage requirement (>11.75%), a rural hospital Must be a public hospital owned or operated by a unit of State or local government OR Must be a private, non-profit hospital under contract with a State or local government to provide health care services to low income individuals not eligible for Medicare or Medicaid Must not purchase outpatient drugs through a Group Purchasing Organization Applies to covered patients only. Facility may utilize a GPO for other patients.

Why Participate in 340B? Cost savings of 20%-50% on outpatient drug purchases Option to purchase outpatient drugs below 340B prices through participation in the 340B Prime Vendor Program (PVP) Option to negotiate reduced prices for inpatient drugs (Current healthcare legislation pending.) Pricing typically 20-25% below negotiated GPO prices. Oncology drugs often 30-40% below GPO prices.

What Drugs Are Covered? Covered drugs: Outpatient Prescription drugs (includes hospital outpatient areas such as ER, OP OR, cancer centers, infusion centers, etc.) Over-the-counter drugs (if accompanied by a written prescription) Non-covered drugs: Vaccines Drugs given to the patient in inpatient care settings (limited exception pricing offered by manufacturers through the prime vendor program.)

Estimated Prices For Selected Public Purchasers, as % Average Wholesale Price 0% 20% 40% 60% 80% 100% AWP 100.0% AMP 80.0% Medicaid (Min.) Medicaid Net FSS 340B FCP 67.9% 60.5% 51.7% 49.0% 47.9% Private Sector Pricing VA Contract 34.6% Stephen Schondelmeyer, PRIME Institute, University of Minnesota (2001)

Savings may be used to: serve more patients expand formulary expand services subsidize prescriptions

Contact hospital s Finance Dept. to obtain Disproportionate Share Adjustment Percentage If >11.75% (based on most recent cost reporting period) Download 340B registration forms If < 11.75% PUBLIC HOSPITALS 340 Program Enrollment Letter PRIVATE NON-PROFIT HOSPITALS STOP HERE! Ineligible for 340B Supporting documentation: Verify state/local Government owned/operated Certification of contract with state/local government Submit all forms to: HRSA/HSB/OPA Mail Stop 10C-03 5600 Fishers Lane Rockville, MD 20857 Certification of non-participation in GPO

Technical Assistance (Key web sites) HRSA Office of Pharmacy Affairs www.hrsa.gov/opa 340B Prime Vendor Program www.340bpvp.com Safety Net for DSH ( Advocacy Organization) www.safetynetrx.org CHRISTUS is a member of the Safety Net organization.

CHRISTUS Implementing a System-Wide 340B Program as a Strategic Sourcing Initiative

Pre-2000 CHRISTUS Initially each facility/region attempted to qualify independently at the direction of the finance department. Only 3/19 facilities had attempted to qualify. No acknowledgement of the supply chain opportunity. Project Initiation After identifying the need for a centralized group effort directed by pharmacy instead of finance the group qualified 15/19 facilities. Two facilities subsequently lost qualification due to patient mix for several quarters after recent hurricanes. With requalification and acquisitions CHRISTUS now has 19/24 facilities qualified.

340B Facility Assessment and Enrollment Business Case: Currently CHRISTUS facilities either qualify or have high potential for DSH enrollment. Based on Broadlane's support and assistance, attempts to enroll the following CHRISTUS facilities will provide cost effective opportunities for the pharmacy programs. Only 3/18 facilities are enrolled at initial evaluation. Benefit Analysis: Contract/Initiative Description Contract Strategy Effective Date 340B Enrollment Support Achieve best outpatient pricing scenario Annualized Outpatient Spend Projected Impact of 340B Program Annualized Increase / (Decrease) to spend 1/1/06 $35,000,000 $9,800,000-28.0% Implementation Timeline / Milestones / Next Steps: All potential facilities(15/19) have qualified as of March 31,2007. Only CHRISTUS St John s, CHRISTUS St Catherine s, CHRISTUS St Patrick s, and CHRISTUS St Michael s do not have sufficient indigent care to qualify at this time. 19/22 potential facilities are qualified as of June 2009. Potential Barriers to Implementation & Recommended Solution Addition of web based software needed for program management. Overly conservative financial calculations by finance departments. Low level of understanding of the federal program by facilities and the potential impact Staff training needs Financial, clinical, pharmacy data interface requirements. Owners: Sam Colletti, BL Pharmacy SLD, Steve Pitzer, CHRISTUS Executive Sponsor

Involvement CHRISTUS Departments Pharmacy, Finance, IT, Social Services, Business Office, Outpatient Services, Corporate Compliance, Corporate Supply Chain Executive Outside Groups GPO( Broadlane) Wholesaler ( McKesson, PHS) Organizations/ Advocacy SNAPHA( Safety Net for Pharmaceutical Access) 340B Prime Vendor Program

Management and Support Tools CHRISTUS currently has enrolled the entire IDN in SNAPHA, an advocacy group for 340B hospitals which provides assistance in managing the program, legal services, and lobbying efforts. CHRISTUS currently utilizes a single program management software solution provided by their wholesaler to provide virtual inventory management, product ordering and audit trails at each 340B qualified facility. CHRISTUS initially added additional consultants with specific expertise in 340b program development. Monitoring and coordination of efforts by GPO consulting staff and Corporate Executive Sponsor.

CHRISTUS Health Previous State 3/19(16%) potential DSH entities qualified No local or system evaluation Annualized Savings under DSH = $2,200,000 Current State 19/24(80%) potential DSH entities qualified 3 entities pending evaluation 2 will not qualify due to local demographics. System Total Drug Spend= $128,000,000 System Outpatient Spend (DSH eligible) = $37,000,000 FY09 Annual Savings under DSH = $9,500,000

Results Change from 16% of all facilities participating in the program to 80% of all facilities. System wide standard for management of the program and compliance with federal regulations. Significant Improvement in profitability of outpatient infusion and oncology services across the system. Significant increase in Community Outreach services without degrading business models.